Atreca, Inc. (NASDAQ:BCEL) Sees Large Increase in Short Interest

Atreca, Inc. (NASDAQ:BCELGet Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 3,310,000 shares, an increase of 7.8% from the December 31st total of 3,070,000 shares. Approximately 11.3% of the shares of the company are sold short. Based on an average daily trading volume, of 8,110,000 shares, the short-interest ratio is presently 0.4 days.

Atreca Stock Performance

Shares of NASDAQ BCEL opened at $0.29 on Thursday. The stock has a market cap of $11.65 million, a P/E ratio of -0.12 and a beta of 1.17. Atreca has a twelve month low of $0.10 and a twelve month high of $2.05. The stock has a 50 day moving average of $0.22 and a two-hundred day moving average of $0.36.

Atreca (NASDAQ:BCELGet Free Report) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). As a group, research analysts predict that Atreca will post -1.61 earnings per share for the current year.

Institutional Investors Weigh In On Atreca

Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC increased its position in Atreca by 2,858.4% in the 2nd quarter. Millennium Management LLC now owns 395,071 shares of the company’s stock valued at $707,000 after acquiring an additional 381,717 shares during the period. Ensign Peak Advisors Inc purchased a new position in shares of Atreca in the 1st quarter valued at approximately $460,000. Renaissance Technologies LLC increased its holdings in shares of Atreca by 4.9% in the first quarter. Renaissance Technologies LLC now owns 297,324 shares of the company’s stock valued at $339,000 after purchasing an additional 14,000 shares during the period. Raymond James & Associates purchased a new stake in shares of Atreca during the first quarter worth approximately $199,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Atreca by 60.5% during the third quarter. Dimensional Fund Advisors LP now owns 96,209 shares of the company’s stock worth $151,000 after purchasing an additional 36,282 shares during the period. 34.91% of the stock is owned by hedge funds and other institutional investors.

About Atreca

(Get Free Report)

Atreca, Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

See Also

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with's FREE daily email newsletter.